Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Carbohydr Polym ; 291: 119610, 2022 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-35698409

RESUMEN

The dissolution behavior of cellulose acetate (CA) is an extremely important property in its extensive applications and preparation of derivatives. In this paper, we proposed a molecular model building strategy to construct amorphous CA with various substituent distributions (different degrees of substitution and substitution positions). A protocol combing molecular dynamics simulation and density functional theory (DFT) was applied to systematically investigate the dissolution behavior of CAs, and the structural properties of CAs. The reduced cohesive energy and polarity of CAs caused by the increase in substituents would enhance its solubility. The interaction of solvent molecules and CAs and the diffusion of solvent molecules in CAs have a synergistic effect on the dissolution of CAs. The diffusion coefficient is the primary factor affecting the solubility. Moreover, substituents at different positions of the anhydroglucose units along the CAs chains would produce different steric hindrance effects, which in turn affect the dissolution behavior.


Asunto(s)
Celulosa , Celulosa/análogos & derivados , Celulosa/química , Solubilidad , Solventes
2.
PLoS One ; 17(6): e0269084, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35648774

RESUMEN

PURPOSE: Cell membrane penetrating peptide BR2 can bind with ganglioside and introduce foreign drugs into tumor cells. In this study, we employed BR2 to carry the broad-spectrum anti-p21Ras scFv prepared in our laboratory into ganglioside expressing tumor cells for therapy of ras-driven tumors. METHODS: BR2-p21Ras scFv gene was cloned to prokaryotic expression vector and expressed in E. coli BL21, then the fusion protein was purified with HisPur Ni-NTA. The immunoreactivity of the fusion protein with p21Ras was detected by ELISA and western blotting. The membrane-penetrating and immune co-localization with p21Ras of the fusion protein were determined by immunofluorescence. The antitumor activity was investigated using MTT, wound healing, colone formation, and apoptosis assays in vitro. RESULTS: BR2-p21Ras scFv fusion protein was successfully expressed and purified. We found that the fusion protein could specifically penetrate into human tumor cell lines which express ganglioside including human neuroblastoma cell line SK-N-SH, human colon cancer cell line HCT116 and human glioma cell line U251. After entering tumor cells the fusion protein bonded specifically with p21Ras. In vitro experiments revealed that it could significantly inhibit the proliferation, migration, and colone formation of HCT116, SK-N-SH, and U251 cells and promote the apoptosis of these tumor cells. CONCLUSIONS: BR2-p21Ras scFv can penetrate ganglioside expressing tumor cells and inhibit the growth of ras-driven tumor by binding with p21Ras, and producing an inhibitory effect. It is suggested that BR2-p21Ras scFv is a potential ras-driven tumor therapeutic antibody.


Asunto(s)
Antineoplásicos , Péptidos de Penetración Celular , Anticuerpos de Cadena Única , Antineoplásicos/farmacología , Línea Celular Tumoral , Gangliósidos , Humanos , Proteínas Proto-Oncogénicas p21(ras)/inmunología , Anticuerpos de Cadena Única/farmacología
3.
Am J Physiol Heart Circ Physiol ; 293(4): H2093-100, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17630351

RESUMEN

Hydrogen sulfide (H(2)S) is a gasotransmitter that regulates cardiovascular functions. The present study aimed to examine the hypothesis that chronic treatment with sodium hydrosulfide (NaHS, an H(2)S donor) is able to prevent left-ventricular remodeling in spontaneously hypertensive rats (SHR). Four-week-old SHR were treated with NaHS (10, 30, and 90 micromol x kg(-1) x day(-1)), a combination of NaHS (30 micromol x kg(-1) x day(-1)) and glibenclamide (5 mg x kg(-1) x day(-1)), glibenclamide alone (5 mg x kg(-1) x day(-1)), hydralazine alone (10 mg x kg(-1) x day(-1)), and placebo for 3 mo. At the end of the treatment period, variables such as cardiac geometry and function, intramyocardial arterioles ranging in diameter from 25 to 100 microm, perivascular and interstitial collagen content, reactive oxygen species (ROS), thiol groups, conjugated dienes, and DNA base modification were examined. The novel finding of the present study is that chronic NaHS treatment prevented the hypertrophy of intramyocardial arterioles and ventricular fibrosis, as well as decreased myocardial ROS and conjugated diene levels. The cardioprotective effects were blunted by coadministration of glibenclamide, suggesting a role of ATP-sensitive potassium channels in mediating the action of NaHS. Hydralazine caused a comparable reduction of blood pressure compared with NaHS treatment; however, it exerted no effect on the remodeling process or on ROS and conjugated diene levels. Moreover, NaHS treatment caused an increase in myocardial thiol group levels, whereas DNA base modification was not altered by NaHS treatment. In conclusion, the superior cardioprotective effects of NaHS treatment are worthy to be further explored to develop novel therapeutic approaches for the treatment of cardiac remodeling in hypertension.


Asunto(s)
Antihipertensivos/farmacología , Cardiotónicos/farmacología , Vasos Coronarios/efectos de los fármacos , Hipertensión/tratamiento farmacológico , Miocardio/patología , Especies Reactivas de Oxígeno/metabolismo , Sulfuros/farmacología , Disfunción Ventricular Izquierda/prevención & control , Remodelación Ventricular/efectos de los fármacos , Animales , Antihipertensivos/uso terapéutico , Análisis Químico de la Sangre , Presión Sanguínea/efectos de los fármacos , Cardiomegalia/etiología , Cardiomegalia/metabolismo , Cardiomegalia/patología , Cardiomegalia/fisiopatología , Cardiomegalia/prevención & control , Cardiotónicos/uso terapéutico , Colágeno/metabolismo , Vasos Coronarios/metabolismo , Vasos Coronarios/patología , ADN/efectos de los fármacos , ADN/metabolismo , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Fibrosis , Gliburida/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Ventrículos Cardíacos/efectos de los fármacos , Ventrículos Cardíacos/metabolismo , Ventrículos Cardíacos/patología , Hidralazina/farmacología , Hipertensión/complicaciones , Hipertensión/metabolismo , Hipertensión/patología , Hipertensión/fisiopatología , Masculino , Miocardio/metabolismo , Estrés Oxidativo/efectos de los fármacos , Ratas , Ratas Endogámicas SHR , Ratas Endogámicas WKY , Compuestos de Sulfhidrilo/metabolismo , Sulfuros/uso terapéutico , Disfunción Ventricular Izquierda/etiología , Disfunción Ventricular Izquierda/metabolismo , Disfunción Ventricular Izquierda/patología , Disfunción Ventricular Izquierda/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...